ArticleFrontiers in nutrition2026
An AI-driven evidence ecosystem for cardiometabolic nutrition: bridging the gap from multiomics to patient empowerment.
Article in Frontiers in nutrition, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cardiometabolic diseases remain a primary global health challenge, with nutritional interventions serving as a critical pillar of management. However, the rapidly expanding volume of nutritional research, spanning high-dimensional multiomics, real-world continuous monitoring, and highly heterogeneous clinical trials, has created fragmented knowledge silos, leading to a profound translation lag between scientific discovery and clinical practice. To overcome this methodological bottleneck, we propose a conceptual framework for an "AI-Driven Evidence Ecosystem." This perspective outlines a four-phase closed-loop architecture: (1) AI-assisted mechanistic decoding of multiomics and the development of digital gut twins; (2) data-optimized clinical research integrating traditional trials with real-world digital biomarkers; (3) a methodologically agnostic, multi-agent living evidence synthesis engine capable of automating complex data extraction and mitigating the translation gap; and (4) the deployment of conversational AI for public knowledge translation and personalized patient empowerment. By addressing concurrent ethical challenges, algorithmic biases, and the risk of researcher de-skilling, this ecosystem paradigm leverages artificial intelligence not merely as an automation tool, but as an indispensable bridge. Ultimately, it transforms isolated, stagnant data into a dynamic, translatable evidence network, reshaping the future of precision cardiometabolic care.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.